Suggested remit: To appraise the clinical and cost effectiveness of tirzepatide within its marketing authorisation for treating type 2 diabetes.
Status In progress
Technology type Medicine
Decision Selected
Process STA 2022
ID number 3938

Provisional Schedule

Committee meeting: 1 07 February 2023
Expected publication 25 April 2023

Project Team

Project lead Thomas Feist

Email enquiries


Key events during the development of the guidance:

Date Update
07 June 2022 Invitation to participate
22 March 2022 - 21 April 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
28 January 2022 In progress. DHSC referral received

For further information on our processes and methods, please see our CHTE processes and methods manual